Quarterly snapshots from biopharma companies with marketed products, including: Amarin, Jazz, United Therapeutics, Vanda.

Quarterly snapshots from biopharma companies with marketed products, including: Intercept, Insmed, Theratechnologies.

Ultragenyx Pharmaceutical Inc.’s top-line win in January with DTX-301 gene therapy in ornithine transcarbamylase (OTC) deficiency seemed to presage even better things to come later this year, and analysts more recently hailed fourth-quarter earnings that showed satisfying progress with Crysvita (burosumab).

Quarterly snapshots from biopharma companies with marketed products, including: Karyopharm.

Quarterly snapshots from biopharma companies with marketed products, including: Acorda, Alkermes, Incyte, Ironwood.

Quarterly snapshots from biopharma companies with marketed products, including: Seattle Genetics, Takeda Pharmaceutical.

Quarterly snapshots from biopharma companies with marketed products, including: Seattle Genetics.

Quarterly snapshots from biopharma companies with marketed products, including: Alnylam, Regeneron.

Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.

Quarterly snapshots from biopharma companies with marketed products, including: Neurocrine.